Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Post-Tamoxifen Exemestane Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* postmenopausal women only~* histologically confirmed stage I-IIIA primary adenocarcinoma of the breast~* estrogen and/or progesterone receptors positive or unknown~* patients should have undergone surgery with a curative intent~* patients must have completed at least 5 years and not more than 7 years of continued treatment with tamoxifen (20 mg/day), while tamoxifen could have been discontinued up to 6 months prior to study entry~* Absence of any evidence of local or distant metastatic disease was required prior to randomization~Exclusion Criteria:~* DCIS, bilateral breast cancer, evidence of metastasis, ER and Pgr negative

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1: observation only (Type: NO_INTERVENTION): Patients have completed at least 5 years and not more than 7 years of continued treatment with tamoxifen (20 mg/day). Tamoxifen could have been discontinued up to 6 months prior to study entry.
- 2: Exemestane (Type: ACTIVE_COMPARATOR): Patients randomised to receive exemestane (25 mg/day) for 5 years, following completion of 5-7 years of Tamoxifen treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).